Clearside Biomedical

(NASDAQ) CLSD

Current PriceN/A

Market CapN/A

Since IPO (2016)-100%

5 Year-100%

1 Year-98%

1 Month-13%

Clearside Biomedical last closing stock price
Metric	Price	Date
Last close	USD 0.25	2026-07-14

Clearside Biomedical stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+99.2%	USD 0.13	2026-07-07
1 month	-12.68%	USD 0.29	2026-06-12
3 month	+17.9%	USD 0.21	2026-04-15
Year to date	-64.68%	USD 0.71	2025-12-31
1 year	-98%	USD 12.44	2025-07-14
3 year	-98.62%	USD 18.00	2023-07-14
5 year	-99.69%	USD 79.35	2021-07-15
Since inception	-99.77%	USD 108.75	2016-06-02

Clearside Biomedical Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$3.33M

Net Income (TTM)

-$26.00M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 12, 2026

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 12, 2026

CLSD News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clearside Biomedical

Clearside develops treatments for eye diseases affecting vision. Its main products help deliver medicine directly to the back of the eye. These solutions aim to improve outcomes for people with serious eye conditions.

Eye on the Prize: Products and Services

XIPERE injectable therapy: FDA-approved treatment for swelling in the eye caused by uveitis; licensed to Bausch + Lomb and Arctic Vision. (No direct product sales revenue reported)
CLS-AX pipeline drug: Investigational therapy for wet age-related macular degeneration, a leading cause of vision loss; Phase 3 ready but not yet in late-stage clinical trials.
CLS-301 pipeline drug: Early-stage treatment for diabetic eye swelling and macular degeneration; not yet in human trials.
SCS Microinjector device: Specialized tool for delivering drugs to the back of the eye; used in both Clearside and partner programs.
Licensing and milestone revenue: Main revenue source, from agreements with partners like Bausch + Lomb, Arctic Vision, and BioCryst; recent revenue is primarily from license agreements and related services to partners.

Growth Spurts and Strategic Moves

XIPERE received FDA approval in 2021; commercialization rights licensed to Bausch + Lomb and Arctic Vision.
2021-2025: Entered partnerships with REGENXBIO, Aura Biosciences, and BioCryst Pharmaceuticals for drug delivery collaborations.
2024: Completed Phase 2b trial for CLS-AX; alignment with FDA on Phase 3 design occurred in the first quarter of 2025.
July 2025: Announced review of strategic alternatives, including possible sale, merger, or partnership; retained Piper Sandler as advisor.
July 2025: Transitioned all employees to consulting roles and paused internal research to conserve cash.

What Makes Clearside Stand Out

Clearside’s drug delivery platform targets the back of the eye, aiming for precise treatment with fewer side effects. Its business model combines internal drug development with licensing and partnerships. The company’s technology is used by several global pharmaceutical partners.

Five Things You Need to Know

Q2 2025 revenue was $492,000, up 446.7% from Q2 2024.
Net loss for Q2 2025 was $4 million, improved 53% from Q2 2024.
Cash and cash equivalents were $9.4 million as of June 30, 2025.
All revenue in 2025 came from licensing, milestones, and device sales.
Company paused all internal R&D and faces risk of Nasdaq delisting.

Bottom Line

Clearside has shifted from internal research to a partnership and licensing model. The company’s future depends on strategic decisions and external collaborations.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

George M. Lasezkay, PharmD

Website

www.clearsidebio.com

Headquarters

Alpharetta, GA 30005, US

CLSD Financials

Key Financial Metrics (TTM)

Gross Margin

89.02%

Operating Margin

-523.09%

Net Income Margin

-618.26%

Return on Equity

37.73%

Return on Capital

-212.13%

Return on Assets

-160.55%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$2.85M

Operating Income

-$22.96M

EBITDA

-$14.37M

Operating Cash Flow

-$21.29M

Capital Expenditure

-$453.00K

Free Cash Flow

-$21.74M

Cash & ST Invst.

$6.80M

Total Debt

$446.00K

Clearside Biomedical Performance Analysis

Clearside Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 29,575,000	N/A
2022	2022-12-31	USD 1,327,000	-95.5%
2023	2023-12-31	USD 8,226,000	519.9%
2024	2024-12-31	USD 1,664,000	-79.8%

Clearside Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	-70.5%
Q1	2025-03-31	661.4%
Q2	2025-06-30	-78.9%
Q3	2025-09-30	-59.1%

Clearside Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD 0.09	N/A
2022	2022-12-31	USD -8.21	N/A
2023	2023-12-31	USD -7.88	-4.0%
2024	2024-12-31	USD -6.98	-11.4%

Clearside Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	3.7%
Q1	2025-03-31	-14.2%
Q2	2025-06-30	47.3%
Q3	2025-09-30	-31.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2025YOY CHG

Revenue

$201.00K

-80.6%

Gross Profit

$201.00K

-80.6%

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$5.97M

+22.3%

EBITDA

-$3.32M

+35.6%

Quarterly Fundamentals

Name

Q3 2025YOY CHG

Total Cash

$6.80M

-71.2%

Total Debt

$446.00K

-99.1%

Accounts Receivable

$266.00K

-66.2%

Inventory

$0.00

N/A

Long Term Debt

$62.00K

-99.9%

Short Term Debt

$384.00K

+2.9%

Return on Assets

-1.61%

N/A

Return on Invested Capital

-1.78%

N/A

Free Cash Flow

-$5.48M

+8.1%

Operating Cash Flow

-$5.48M

+7.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CASICASI Pharmaceuticals, Inc.

CASICASI Pharmaceuticals, Inc.$0.15+3.08%

CINGCingulate Inc.

CINGCingulate Inc.$4.37-1.35%

LSTALisata Therapeutics, Inc.

LSTALisata Therapeutics, Inc.$3.64+4.00%

ALLRAllarity Therapeutics, Inc.

ALLRAllarity Therapeutics, Inc.$1.16-0.85%

ENTOEntero Therapeutics, Inc.

ENTOEntero Therapeutics, Inc.$2.85-5.00%

MTVAMetaVia Inc.

MTVAMetaVia Inc.$1.73-3.89%

PALIPalisade Bio, Inc.

PALIPalisade Bio, Inc.$1.98+4.76%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.07-0.05%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$27.44-0.00%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.99+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.36-0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.16-0.03%

NOKNokia

NOKNokia$10.09-0.03%

NFLXNetflix

NFLXNetflix$67.67-0.09%

Questions About CLSD

What is the current price of Clearside Biomedical?

Clearside Biomedical is trading at N/A per share.

What is the 52-week range for Clearside Biomedical?

Over the past 52 weeks, Clearside Biomedical has traded between N/A and N/A.

How much debt does Clearside Biomedical have?

As of the most recent reporting period, Clearside Biomedical reported total debt of $61.61M.

How much cash does Clearside Biomedical have on hand?

Clearside Biomedical reported $6.80M in cash and cash equivalents in its most recent financial results.

What is Clearside Biomedical’s dividend yield?

Clearside Biomedical does not currently have a dividend yield.

Clearside Biomedical

Clearside Biomedical Financials at a Glance

CLSD News

Why Clearside Biomedical Stock Surged Today

Clearside Biomedical Stock Down 26%: The "Positive" Data That Wasn't

Why Clearside Biomedical, Inc. Stock Gained 66.1% March

Why Clearside Biomedical Is Up for a Third Straight Day

Why Clearside Biomedical Jumped Higher Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Clearside Biomedical

Eye on the Prize: Products and Services

Growth Spurts and Strategic Moves

What Makes Clearside Stand Out

Five Things You Need to Know

Bottom Line

CLSD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Clearside Biomedical Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CLSD

What is the current price of Clearside Biomedical?

What is the 52-week range for Clearside Biomedical?

How much debt does Clearside Biomedical have?

How much cash does Clearside Biomedical have on hand?

What is Clearside Biomedical’s dividend yield?

Premium Investing Services